Amyloid Neuropathies clinical trials

The registry lists 15 studies for Amyloid Neuropathies across more than 10 countries. 3 are recruiting or about to start. 4 of them are mainly about Amyloid Neuropathies (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its 2 narrower conditions too, such as Amyloid Neuropathies, Familial: 244 studies, 112 open.

Get an email when these change. Save the Amyloid Neuropathies studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 6
Active, not recruiting: 2
Recruiting: 2
Withdrawn: 2
Approved for marketing: 1
Status unknown: 1

Phase

Phase 3: 4
Phase 1: 1

Where

United States: 6
Spain: 6
Brazil: 5
Germany: 5
France: 5
Argentina: 4

Who runs them

Alnylam Pharmaceuticals (6) · CENTOGENE GmbH Rostock (2) · University of Sao Paulo General Hospital (1) · Hospital Italiano de Buenos Aires (1) · Intellia Therapeutics (1) · AstraZeneca (1) · Assistance Publique Hopitaux De Marseille (1) · University Hospital, Antwerp (1)

What is being tested here

Drugs under test in Amyloid Neuropathies studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Phase 3	All
NTLA-2001	1	1
Patisiran	1	1
Vutrisiran	0	1
Revusiran	1	1

Coming up

2phase 3 studies under way

1study finishes main data collection within a yearphase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Jul 2027A Phase 3 Study of NTLA-2001 in ATTRv-PN · Phase 3 · Intellia Therapeutics

Who these studies take

Of the 2 Amyloid Neuropathies studies recruiting now, 1 (50%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 2
Age	Women	Men
10	1 (50%)	1 (50%)
18	2 (100%)	2 (100%)
30	2 (100%)	2 (100%)
40	2 (100%)	2 (100%)
50	2 (100%)	2 (100%)
65	2 (100%)	2 (100%)
75	2 (100%)	2 (100%)
85	2 (100%)	2 (100%)

Across all 15 studies, recruiting or not: 7% stop at 75 or younger and 7% at 65; 13% take children; 0% are for women only and 0% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 15 of 15. search them.